-
By 2007, the prevalence of fluoroquinolone resistance among N. gonorrhoeae had become so widespread in the United States that the CDC recommended against use of drugs of that class in the treatment of gonorrhea.
-
The Black Women's Health Imperative in Washington, DC, has found that a two-pronged program that targets teen-age African American girls and their mothers or other family members has the potential for being a very successful, intergenerational HIV prevention approach.
-
A total of 1,763 HIV-1 serodiscordant couples in nine countries with the infected partner having CD4+ counts of 350-500/mL were randomized 1:1 to early (immediate) vs. delayed (CD4+ had declined to ¡Ü 250/mL or after development of an AIDS-related illness) antiretroviral therapy of the infected partner.
-
With the Centers for Disease Control and Prevention's (CDC's) new HIV prevention focus on scientifically proven, cost-effective, and scalable interventions targeted to the right populations, some experts worry black women will be left a low priority on the formula. And federal funding for small, hands-on prevention programs that work holistically with women of color might dry up entirely.
-
A California-based company is looking at new condom designs, including a male non-rolled silicone condom, a female silicone condom, and a silicone condom designed specifically for receptive anal intercourse. All three designs of Origami condoms are in early research stages at Culver City, CA-based Strata Various Product Designs.
-
On Aug. 10, 2011, the Food and Drug Administration (FDA) approved Complera, a fixed dose combination (FDC) drug product containing emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) for the treatment of HIV. The recommended dose of Complera is one tablet, containing 200mg/25mg/300mg of FTC/RPV/TDF, once daily, taken orally with a meal.
-
The Joint Commission recently posted the following answer to a frequently asked question on screening for methicillin-resistant Staphylococcus aureus (MRSA).
-
The elements of performance for the CAUTI prevention safety goal are as follows:
-
The Joint Commission's new National Patient Safety Goal (NPSG) on preventing indwelling catheter-associated urinary tract infections which emphasizes prompt removal of unnecessary devices and surveillance for CAUTIs is effective January 1, 2012 for hospitals.
-
Field test results of an integrated microfluidic-based diagnostic device indicate that the potential